8,190 Shares in IQVIA Holdings Inc. $IQV Acquired by Vise Technologies Inc.

Vise Technologies Inc. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 8,190 shares of the medical research company’s stock, valued at approximately $1,583,000.

Other large investors have also recently made changes to their positions in the company. International Assets Investment Management LLC bought a new stake in IQVIA during the fourth quarter worth $27,000. Gilpin Wealth Management LLC bought a new stake in IQVIA in the 4th quarter worth about $27,000. CrossGen Wealth LLC purchased a new position in IQVIA in the fourth quarter worth $28,000. Activest Wealth Management increased its holdings in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after buying an additional 118 shares during the last quarter. Finally, Financial Freedom LLC bought a new position in IQVIA during the first quarter valued at $25,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Up 1.6%

Shares of NYSE IQV opened at $260.17 on Friday. The firm’s 50 day simple moving average is $213.32 and its two-hundred day simple moving average is $187.52. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $260.40. The stock has a market capitalization of $42.82 billion, a P/E ratio of 32.28, a PEG ratio of 2.17 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has initiated a share repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IQV. JPMorgan Chase & Co. raised their price objective on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Mizuho raised their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Robert W. Baird boosted their price objective on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Finally, TD Cowen upped their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $241.88.

Insider Transactions at IQVIA

In related news, insider W Richard Staub sold 5,500 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 over the last 90 days. 1.70% of the stock is currently owned by insiders.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.